Altria: The Former Parent Turned CounterpartyNarrow moat

Philip Morris International (PM) — moat facet

Altria was PMI's parent, its IQOS partner and the seller of the IQOS rights, and from 2027 it will buy cigarettes PMI makes for it.

No rival has as tangled a history with PMI as Altria. PMI was its subsidiary until March 2008, when it became a separate company listed on the New York Stock Exchange1. The two agreed that PMI would sell internationally and Altria in the United States, which is why PMI does not sell cigarettes in America.

PMI and AltriaMar 2008spin-off,NYSE listing20 Oct 2022IQOSarrangementended1 May 2024US IQOS rightsto PMI, $2.8bn24 Aug 2026contractmanufacturingdealEarly 2027first shipmentsPMI Form 10-K FY2025; contract manufacturing release August 2026
Parent, partner, seller, customer.

Then came IQOS. Altria sold PMI's heated device in the United States until the two agreed on 20 October 2022 to end the arrangement, with PMI taking the full American rights from 1 May 2024 for a total of $2.8 billion including interest2. The former parent was paid to step aside.

In August 2026 the relationship turned again. PMI agreed to manufacture combustible cigarettes under contract for Philip Morris USA, Altria's operating company, with first shipments expected early in 2027, while stating that "PMI has not commercialized combustible cigarettes in the United States and has no plans to do so"3. PMI will make cigarettes for the company it competes with in nicotine pouches and heated tobacco.

That makes Altria a competitor, a former seller of rights and a customer at once. The contract adds a little volume to PMI's factories; it also confirms the old division of the world.

Altria was worth $114.91 billion in September 20264, against PMI's $296.88 billion5, about 2.6 times smaller6. The ratio is the market's judgment of the two strategies, and a narrowing would suggest Altria's American cigarette cash is being valued above PMI's international transition.

Moat trajectory: Holding steady

Contract manufacturing from 2027; US division of markets unchanged.

The number that tests this moat
Moat Explorer calc
Market value relative to Altria
About 2.6 times ($296.88bn vs $114.91bn, September 2026)

The market's judgment of the two strategies; a narrowing would favour Altria's American cigarette cash.

How it's calculated: PMI market capitalisation divided by Altria's, stockanalysis data at 25 September 2026.
Source: Moat Explorer calculation from PMI filings ↗
References
  1. ReportedPMI was its subsidiary until March 2008, when it became a separate company listed on the New York Stock Exchange.
    Philip Morris International Form 10-K for fiscal 2025 - Item 1 business: markets, products, competitors, market shares, shipments and employees. — FY2025 · publ. 6 February 2026 · source ↗
  2. ReportedAltria sold PMI's heated device in the United States until the two agreed on 20 October 2022 to end the arrangement, with PMI taking the full American rights from 1 May 2024 for a total of $2.8 billion including interest.
    Philip Morris International Form 10-K for fiscal 2025 - financial statements and notes: income statement, excise, cash flow, debt, acquisitions and impairments. — FY2025 · publ. 6 February 2026 · source ↗
  3. ReportedPMI agreed to manufacture combustible cigarettes under contract for Philip Morris USA, Altria's operating company, with first shipments expected early in 2027, while stating that "PMI has not commercialized combustible cigarettes in the United States and has no plans to do so".
    Philip Morris International release, 24 August 2026 - contract manufacturing of combustible cigarettes for Philip Morris USA. — August 2026 · publ. 24 August 2026 · source ↗
  4. ReportedAltria was worth $114.91 billion in September 2026, against PMI's $296.88 billion, about 2.6 times smaller.
    Philip Morris International market capitalisation history - year-end values 2015-2025, and peers British American Tobacco and Altria. — 2015-2026 · publ. September 2026 · source ↗
  5. ReportedAltria was worth $114.91 billion in September 2026, against PMI's $296.88 billion, about 2.6 times smaller.
    Philip Morris International (PM) market data - $190.48 a share at the close on 25 September 2026, market cap $296.88B, 52-week range 142.11-207.76, beta 0.40, 16 analysts with a consensus Buy rating and a price target of $208.13. — September 2026 · publ. 25 September 2026 · source ↗
  6. Moat Explorer calcAltria was worth $114.91 billion in September 2026, against PMI's $296.88 billion, about 2.6 times smaller.
    Moat Explorer calculation from Philip Morris International's reported figures ($ millions unless stated). Excise and revenue 2025: 53,211 / 40,648 = 1.31 dollars of excise per dollar of net revenue; gross of excise 53,211 + 40,648 = 93,859, excise share 53,211 / 93,859 = 56.7%; excise growth 2023-2025 53,211 / 49,404 - 1 = 7.7% against net revenue growth 40,648 / 35,174 - 1 = 15.6%. Product mix 2025: smoke-free 16,854 / 40,648 = 41.5%; combustible 23,794 / 40,648 = 58.5%; smoke-free 2023 12,840 / 35,174 = 36.5%, 2024 14,660 / 37,878 = 38.7%; smoke-free growth 2023-2025 16,854 / 12,840 - 1 = 31.3%; smoke-free revenue 2016 733 to 2025 16,854 = 23 times. Segments 2025: International Smoke-Free 13,996 / 40,648 = 34.4%; International Combustibles 23,436 / 40,648 = 57.7%; U.S. 3,216 / 40,648 = 7.9%; recast gross profit shares 9,576 / 27,304 = 35.1%, 15,523 / 27,304 = 56.9%, 2,206 / 27,304 = 8.1%. Growth 2025: ISF 13,996 / 12,126 - 1 = 15.4%; IC 23,436 / 22,807 - 1 = 2.8%; U.S. 3,216 / 2,944 - 1 = 9.2%. Growth 2024: ISF 12,126 / 11,102 - 1 = 9.2%; IC 22,807 / 21,903 - 1 = 4.1%; U.S. 2,944 / 2,169 - 1 = 35.7%. IC gross profit 15,523 / 13,972 - 1 = 11.1% against IC revenue 23,436 / 21,903 - 1 = 7.0% (2023-2025). Recast reported gross margins 2023: ISF 7,021 / 11,102 = 63.2%, IC 13,972 / 21,903 = 63.8%; 2024: ISF 7,831 / 12,126 = 64.6%, IC 14,687 / 22,807 = 64.4%. Segment sum 2024 12,126 + 22,807 + 2,944 = 37,877 against 37,878 reported. IC shares of net revenues 21,903 / 35,174 = 62.3% (2023), 22,807 / 37,878 = 60.2% (2024). U.S. revenue 3,216 / 2,169 - 1 = 48.3% (2023-2025). Q2 2026 shares: ISF 3,877 / 11,192 = 34.6%, IC 6,459 / 11,192 = 57.7%, U.S. 856 / 11,192 = 7.6%. U.S. gross margin Q2 2026 555 / 856 = 64.8% against 611 / 862 = 70.9%. Swedish Match: 14,460 + 1,495 + 883 = 16,838 total cash paid; U.S. adjusted operating companies income 1,124 / 16,838 = 6.7% pre-tax; reported U.S. OCI 322 / 3,216 = 10.0% of U.S. revenue; adjusted 1,124 / 3,216 = 35.0%. Goodwill and other intangibles 17,264 + 10,884 = 28,148, 28,148 / 69,185 = 40.7% of total assets. Volumes: cigarettes 607,367 / 616,827 - 1 = -1.5% (2025), 607,367 / 612,949 - 1 = -0.9% (2023-2025); heated tobacco units 155,133 / 139,743 - 1 = 11.0% (2025), 139,743 / 125,263 - 1 = 11.6% (2024); HTUs 155,133 / (607,367 + 155,133) = 20.3% of cigarette plus HTU shipments. U.S. ZYN cans 793.7 / 384.8 = 2.06 times (2023-2025), 793.7 / 580.5 - 1 = 36.7% (2025); international nicotine pouches 879.6 - 793.7 = 85.9 million cans (2025), 644.0 - 580.5 = 63.5 (2024); snus 227.9 / 240.4 - 1 = -5.2% (2023-2025); e-vapor 3,330 / 1,651 = 2.0 times. U.S. segment: cigars 358 / 410 - 1 = -12.7%, 358 / 431 - 1 = -16.9% (2023-2025); wellness 238 / 333 - 1 = -28.5%. Cash and dividends: free cash flow 12,233 - 1,569 = 10,664 (2025), 12,217 - 1,444 = 10,773 (2024), 9,204 - 1,321 = 7,883 (2023); dividends paid / free cash flow 8,624 / 10,664 = 80.9% (2025), 8,197 / 10,773 = 76.1% (2024), 7,964 / 7,883 = 101.0% (2023). Payout of declared dividends per share over diluted EPS: 5.64 / 7.26 = 77.7% (2025), 5.30 / 4.52 = 117.3% (2024), 5.14 / 5.02 = 102.4% (2023); over adjusted EPS 5.64 / 7.54 = 74.8%. Annualised dividend 1.60 x 4 = 6.40; 6.40 / 5.64 = 1.13; dividend 5.64 / 1.54 = 3.7 times since 2008; yield 6.40 / 190.48 = 3.4%. R&D 756 / 40,648 = 1.9% of revenue; capex 1,569 / 40,648 = 3.9%. Customers: two customers 12% + 10% = 22% of 2025 net revenues; related-party revenue 4,582 / 40,648 = 11.3%; Megapolis 2,805 / 40,648 = 6.9%; Megapolis growth 2,805 / 2,393 - 1 = 17.2%. Japan 4.2 / 40.6 = 10.3% of net revenues. Canada: RBH carrying value 3,280 fair value at deconsolidation to 51 at 30 June 2026; impairments 2,316 + 511 = 2,827. Valuation: trailing twelve months to June 2026 revenue 40,648 + 21,338 - 19,441 = 42,545; net earnings 11,348 + 5,255 - 5,729 = 10,874; P/E 296.88 / 10.874 = 27.3; P/S 296.88 / 42.545 = 6.98; 2018 P/E 103.78 / 7.911 = 13.1; 2025 P/E 249.68 / 11.348 = 22.0; free cash flow yield 10,664 / 296,880 = 3.6%. Other PMI cigarette brands: 25.4 - 9.8 = 15.6% (2023), 25.3 - 10.7 = 14.6% (2025), a loss of 1.0 point against Marlboro's gain of 0.9. Excise Q2 2026 14,973 / 13,272 - 1 = 12.8% against net revenues 11,192 / 10,140 - 1 = 10.4%. U.S. smoke-free H1 1,584 - 1,311 = 273 decline. ISF H1 2026 gross margin 5,400 / 7,713 = 70.0%. Gross margin 2025 27,282 / 40,648 = 67.1%. ROIC average 2015-2025 (45.6 + 50.2 + 43.4 + 50.7 + 48.7 + 52.1 + 57.2 + 40.6 + 26.8 + 28.6 + 32.5) / 11 = 43.3%. Employees 84,900 - 82,700 = 2,200 (2023-2025); net revenues 40,648 - 35,174 = 5,474, about 5.5 billion. Snus 240.4 - 227.9 = 12.5 million cans. Europe smoke-free 8,127 / 16,854 = 48.2%, about half. Cigarette decline 2% to 3% of 607,367 = 12,147 to 18,221 million units. Operating cash flow over R&D 12,233 / 756 = 16.2 times. Blocked markets 440 / 2,587 = 17%, about a sixth. Market cap against peers 296.88 / 119.41 = 2.5 times British American Tobacco; 296.88 / 114.91 = 2.6 times Altria. Net debt to adjusted EBITDA 43,963 / 17,375 = 2.53. Interest 966 / 14,892 = 6.5% of operating income. Guidance midpoints: (8.35 + 8.50) / 2 = 8.43, reported (7.28 + 7.43) / 2 = 7.36, gap 8.43 - 7.36 = 1.07; earlier adjusted midpoints (8.38 + 8.53) / 2 = 8.46, (8.31 + 8.46) / 2 = 8.39, (8.26 + 8.41) / 2 = 8.34; 8.43 / 7.54 - 1 = 11.8% - growth rates, volumes, margins and excise. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in PMI's Forms 10-K and 10-Q, the recast segment schedules, results releases and market data; operands shown in the source line.
Sources
Generated September 26, 2026